Zacks Research Has Negative Outlook for TSE:BHC Q3 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research lowered their Q3 2027 earnings per share (EPS) estimates for Bausch Health Companies in a report released on Monday, October 27th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.68 for the quarter, down from their previous forecast of $1.69. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2027 earnings at $6.08 EPS.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at C$8.62 on Tuesday. The business’s 50-day simple moving average is C$9.40 and its 200 day simple moving average is C$8.39. The stock has a market cap of C$3.19 billion, a price-to-earnings ratio of 33.15, a P/E/G ratio of 0.21 and a beta of 0.68. Bausch Health Companies has a 12-month low of C$5.91 and a 12-month high of C$13.74. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of -1,831.94.

About Bausch Health Companies

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.